我们是否信任科学证据?OPTIMIST试验前后首周期IVF/ICSI的多中心回顾性分析
结果显示OPTIMIST试验对日常实践影响有限,标准150 IU处方总体增加、>300 IU起始剂量使用减少,依从性仍普遍较差。
要点
- OPTIMIST试验后标准150 IU起始剂量处方总体增加,>300 IU使用减少。
- >300 IU剂量的下降在预测卵巢低反应和正常反应亚组中仍显著。
- 临床医生采纳RCT推荐可能较慢,需加强证据传播与推广。
核心结论
- OPTIMIST试验对ART日常实践的影响有限,临床对其推荐的依从性仍普遍较差。
研究设计与样本
- 按卵巢储备标志物将患者分为预测卵巢低反应组、预测正常反应组和预期高反应组。
主要发现
- 2017年至2018年,OPTIMIST试验提出的标准150 IU剂量处方总体增加,>300 IU起始剂量使用减少。
- 亚组分析后,>300 IU剂量的下降在预测卵巢低反应组和正常反应组中仍显著。
临床怎么用
- 临床医生在制定重组FSH起始剂量时可参考OPTIMIST试验结果,但证据转化至日常实践可能较慢。
局限性
- 研究为回顾性设计,医生适应新科学证据需要时间,且不能确定观察到的变化可归因于对OPTIMIST试验的了解。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Has the practice of individualizing the recombinant-FSH starting dose been superseded after the largest randomized controlled trial (RCT) in assisted reproduction technology (ART), the OPTIMIST trial? SUMMARY ANSWER: The OPTIMIST trial has influenced our ART daily practice to a limited degree, but adherence is still generally poor. WHAT IS KNOWN ALREADY: Although the 'one size fits all' approach has been discouraged for decades by most authors, the OPTIMIST study group demonstrated in a large prospective RCT that, in general, dosage individualization does not improve the prospects for live birth, although it may decrease ovarian hyperstimulation syndrome (OHSS) risk in expected high responders. STUDY DESIGN, SIZE, DURATION: Retrospective analysis of all first in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) cycles from 1st January 2017 to 31st December 2018, before and after the OPTIMIST publication on November 2017. PARTICIPANTS/MATERIALS, SETTING, METHODS: Two thousand six hundred and seventy-seven patients, between 18 and 42 years old, undergoing their first IVF-ICSI cycle in seven Italian fertility centres, were included. Patients were allocated to three groups according to their ovarian reserve markers: predicted poor ovarian responders (POR), predicted normo-responders (NR) and expected hyper-responders (HRs). MAIN RESULTS AND THE ROLE OF CHANCE: Between 2017 and 2018, there was an overall increase in prescription of the standard 150 IU dose proposed by the OPTIMIST trial and a reduction in the use of a starting dose >300 IU. After subgroup analysis, the decrease in doses >300 IU remained significant in the POR and NR sub-groups. LIMITATIONS, REASONS FOR CAUTION: The retrospective nature of the study. Physicians need time to adapt to new scientific evidence and a comparison between 2017 and 2019 may have found a greater impact of the Optimist trial, although other changes over the longer time span might have increased confounding. We cannot be sure that the observed changes can be attributed to knowledge of the OPTIMIST trial. WIDER IMPLICATIONS OF THE FINDINGS: Clinicians may be slow to adopt recommendations based on RCTs; more attention should be given to how these are disseminated and promoted. STUDY FUNDING/COMPETING INTEREST(S): No external funding was used for this study. E.P. reports grants and personal fees from MSD, grants from Ferring, from IBSA, grants and personal fees from Merck, grants from TEVA, grants from Gedeon Richter, outside the submitted work. E.S. reports grants from Ferring, grants and personal fees from Merck-Serono, grants and personal fees from Theramex, outside the submitted work. All other authors do not have conflicts of interest to declare. TRIAL REGISTRATION NUMBER: Not applicable.
引用
- Papaleo E, Revelli A, Costa M, et al. Do we trust scientific evidence? A multicentre retrospective analysis of first IVF/ICSI cycles before and after the OPTIMIST trial. Hum Reprod. 2021. PMID: 33686407. doi:10.1093/humrep/deab047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。